| FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer X Fu, R Jeselsohn, R Pereira, EF Hollingsworth, CJ Creighton, F Li, ... Proceedings of the National Academy of Sciences 113 (43), E6600-E6609, 2016 | 159 | 2016 |
| FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer X Fu, R Pereira, C De Angelis, J Veeraraghavan, S Nanda, L Qin, ... Proceedings of the National Academy of Sciences 116 (52), 26823-26834, 2019 | 128 | 2019 |
| Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer C De Angelis, X Fu, ML Cataldo, A Nardone, R Pereira, J Veeraraghavan, ... Clinical Cancer Research 27 (17), 4870-4882, 2021 | 66 | 2021 |
| Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer V Sethunath, H Hu, C De Angelis, J Veeraraghavan, L Qin, N Wang, ... Molecular Cancer Research 17 (11), 2318-2330, 2019 | 56 | 2019 |
| Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models J Veeraraghavan, C Gutierrez, V Sethunath, S Mehravaran, M Giuliano, ... NPJ Breast Cancer 7 (1), 63, 2021 | 6 | 2021 |
| Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer C De Angelis, X Fu, ML Cataldo, A Nardone, VM Jansen, ... Cancer Research 80 (4_Supplement), GS2-01-GS2-01, 2020 | 5 | 2020 |
| PIN34 A CONTINUOUS-TIME ECONOMIC MODEL TO EVALUATE RALTEGRAVIR USE STRATEGIES IN TREATMENT-NAIVE HIV-1 PATIENTS IN PORTUGAL MA Chaudhary, EH Elbasha, R Pereira, RN Kumar Value in Health 7 (13), A436, 2010 | 4 | 2010 |
| Myelin-reactive B cells exacerbate CD4+ T cell-driven CNS autoimmunity in an IL-23-dependent manner MR Fazazi, PMIA Doss, R Pereira, N Fudge, A Regmi, C Joly-Beauparlant, ... Nature Communications 15 (1), 5404, 2024 | 2 | 2024 |
| Hyperactive FOXA1 activates super-enhancer-engaged HIF2 alpha/EPAS1 to promote endocrine-resistant metastatic ER-positive breast cancer X Fu, R Pereira, C De Angelis, J Veeraraghavan, MJ Shea, S Nanda, ... CANCER RESEARCH 78 (4), 2018 | 2 | 2018 |
| FOXA1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer X Fu, R Pereira, D Zhao, SY Jung, R Jeselsohn, CJ Creighton, M Shea, ... CANCER RESEARCH 77, 2017 | 2 | 2017 |
| Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer X Fu, R Pereira, L Qin, C De Angelis, S Nanda, M Shea, A Nardone, ... Cancer Research 81 (4_Supplement), PD8-03-PD8-03, 2021 | 1 | 2021 |
| A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer X Fu, R Pereira, L Qin, C De Angelis, S Nanda, M Shea, A Nardone, ... CANCER RESEARCH 81 (4), 2021 | 1 | 2021 |
| Texture Analysis Shows Promise in Differentiating Pancreatic Neoplasms RR Pereira Academic Radiology 27 (6), 824, 2020 | 1 | 2020 |
| High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER plus breast cancer C De Angelis, X Fu, ML Cataldo, A Nardone, VM Jansen, ... CANCER RESEARCH 80 (4), 2020 | 1 | 2020 |
| Myelin-reactive B cells exacerbate the severity of CD4+ T cell-driven CNS autoimmunity in an IL-23-dependent manner MR Fazazi, PMI Arokia Doss, R Pereira, N Fudge, A Regmi, I Akbar, ... bioRxiv, 721696, 2019 | 1 | 2019 |
| High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer X Fu, R Pereira, CC Liu, C De Angelis, MJ Shea, S Nanda, L Qin, ... Cell Reports 42 (8), 2023 | | 2023 |
| Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer CC Liu, L Qin, C De Angelis, S Nanda, R Pereira, MJ Shea, A Nardone, ... CANCER RESEARCH 82 (4), 2022 | | 2022 |
| Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer CC Liu, L Qin, C De Angelis, S Nanda, R Pereira, MJ Shea, A Nardone, ... Cancer Research 82 (4_Supplement), PD1-05-PD1-05, 2022 | | 2022 |
| Sex differences in stroke dysbiosis in rodent models of focal cortical ischemia E Daniele University of Toronto (Canada), 2022 | | 2022 |
| Abstract PD2-02: Activation of the EGFR/RAS/p42, 44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer C De Angelis, ML Cataldo, A Nardone, J Veeraraghavan, X Fu, S Nanda, ... Cancer Research 80 (4_Supplement), PD2-02-PD2-02, 2020 | | 2020 |
